[
  {
    "ts": null,
    "headline": "Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?",
    "summary": "Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=c3487cf139b09e9cdfefdbfaf0bbdcb2571e480b778702537e0a4adab7c09ce1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749051026,
      "headline": "Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?",
      "id": 135038540,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=c3487cf139b09e9cdfefdbfaf0bbdcb2571e480b778702537e0a4adab7c09ce1"
    }
  },
  {
    "ts": null,
    "headline": "Down 80%, Should You Buy the Dip on Moderna?",
    "summary": "Moderna stock has dropped along with demand for a product that once drove tremendous growth: the coronavirus vaccine.  Investors have remained focused on those declines -- and haven’t yet recognized Moderna’s long-term potential.  A few years ago, Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win.",
    "url": "https://finnhub.io/api/news?id=dcf9d53e5decdf5b2525a8985c4b79e039bf0ea193a38155612aa7f01e7d138f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749024900,
      "headline": "Down 80%, Should You Buy the Dip on Moderna?",
      "id": 135008997,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna stock has dropped along with demand for a product that once drove tremendous growth: the coronavirus vaccine.  Investors have remained focused on those declines -- and haven’t yet recognized Moderna’s long-term potential.  A few years ago, Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win.",
      "url": "https://finnhub.io/api/news?id=dcf9d53e5decdf5b2525a8985c4b79e039bf0ea193a38155612aa7f01e7d138f"
    }
  }
]